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Summary
The Kaposi’s sarcoma-associated herpesvirus (KSHV), the infectious causative agent of Kaposi’s sarcoma (KS), encodes a G
protein-coupled receptor (vGPCR) implicated in the initiation of KS. Here we demonstrate that Kaposi’s sarcomagenesis
involves stimulation of tuberin (TSC2) phosphorylation by vGPCR, promoting the activation of mTOR through both direct
and paracrine mechanisms. Pharmacologic inhibition of mTOR with rapamycin prevented vGPCR sarcomagenesis, while
overactivation of this pathway was sufficient to render endothelial cells oncogenic. Moreover, mice haploinsufficient for
TSC2 are predisposed to vascular sarcomas remarkably similar to KS. Collectively, these results implicate mTOR in KS
initiation and suggest that the sarcomagenic potential of KSHV may be a direct consequence of the profound sensitivity
of endothelial cells to vGPCR dysregulation of the TSC2/mTOR pathway.Introduction
The PI3K/Akt pathway is a critical intracellular route in the regu-
lation of several cellular processes that represent hallmarks of
cancer, including cell proliferation and survival, cell size and
response to nutrient availability, intermediary metabolism, an-
giogenesis, and tissue invasion (Luo et al., 2003). Indeed,
many cellular and viral oncoproteins as well as tumor suppres-
sor proteins intersect at the PI3K/Akt pathway, harnessing the
oncogenic potential of these signalingmolecules to drive tumor-
igenesis (Vivanco and Sawyers, 2002). Amplification of the akt
genes and activating mutations in the PI3K subunits have
been found in several human tumors (Samuels et al., 2004;
Thompson and Thompson, 2004). Conversely, PTEN (phospha-
tase and tensin homolog deleted on chromosome ten),
a negative regulator of the PI3K/Akt pathway, is one of the
most frequently mutationally inactivated tumor suppressor
genes in human cancer (Parsons, 2004; Samuels et al., 2004),CANCER CELL 10, 133–143, AUGUST 2006 ª2006 ELSEVIER INC. DOI 1underscoring the sensitivity of cells to the dysregulation of this
important signaling route.
Akt has a wide range of cellular targets, and its oncogenicity
arises through its regulation of multiple proliferative and antia-
poptotic intracellular pathways (Downward, 2004). Recent ef-
forts have focused on identifying the relative contribution of
these Akt downstream routes to cell transformation. In particu-
lar, Akt has recently been recognized as an essential link be-
tween the PI3K pathway and the mammalian target of rapamy-
cin (mTOR) through the inactivation of the tuberous sclerosis
complex (TSC) (Manning and Cantley, 2003; Richardson et al.,
2004). The TSC complex, formed by hamartin (TSC1) and tu-
berin (TSC2), functions as a negative regulator (a GTPase-
activating protein or GAP) for Rheb, a Ras-related small GTP
binding protein that promotes the activation of mTOR (Garami
et al., 2003; Inoki et al., 2003; Tee et al., 2003). Phosphorylation
of the tumor suppressor TSC2 by Akt results in the inactivation
of this Rheb GAP, thereby promoting the accumulation ofS I G N I F I C A N C E
Coincidentwith theAIDS epidemic, the incidenceof Kaposi’s sarcoma (KS) has risendramatically,making this oncerareneoplasm one of
the most frequent cancers in parts of the developing world. Emerging efforts are now focused on defining molecular targets for the treat-
ment of this disease. Of interest, endothelial-specific expression of one KSHV-encoded gene, vGPCR, is sufficient to induce Kaposi-like
sarcomas in mice, implicating this viral oncogene in KS development. Here we demonstrate that Akt activation of the TSC2/mTOR path-
way is necessary and sufficient for vGPCR oncogenesis. These results implicate the mTOR signaling route in Kaposi’s sarcomagenesis and
provide experimental evidence demonstrating that drugs targeting mTOR may represent an effective mechanism-based therapy for the
treatment of patients with KS.0.1016/j.ccr.2006.05.026 133
A R T I C L E(active) Rheb-GTP and the induction of mTOR activity. mTOR
then triggers the phosphorylation of key regulators of the cellular
translation machinery, including ribosomal p70 S6 kinase (p70
S6K) and eukaryote initiation factor 4E binding protein 1
(4EBP1) (Aoki et al., 2001; Gingras et al., 1998).
Recent work examining the regulation of the mTOR pathway
has highlighted its impact on the control of cell growth and
has emphasized its importance in human cancer (Luo et al.,
2003; Manning, 2004). Indeed, dysregulated mTOR activity is
associated with several hamartoma syndromes, all caused by
mutations in tumor-suppressor genes that negatively regulate
mTOR (Inoki et al., 2005). Emerging evidence now suggests
that the TSC2/mTOR pathway may also play a critical role in
the progression of tumors dependent on Akt activation, making
this serine-threonine kinase an attractive target for the develop-
ment of novel mechanism-based drug therapies (Majumder
et al., 2004; Wislez et al., 2005).
In this regard, the Kaposi’s sarcoma-associated herpesvirus
(KSHV), the human herpesvirus that causes the vascular tumor
Kaposi’s sarcoma (KS), encodes a G protein-coupled receptor
(vGPCR) that has been shown to promote the constitutive acti-
vation of PI3K/Akt (Montaner et al., 2001), implicating this path-
way in the genesis of this unusual neoplasm. KS, a multifocal tu-
mor that affects the skin, oral mucosa, lymph nodes, and
visceral organs, remains the most common cancer in HIV-
infected individuals (Moore and Chang, 2001). Indeed, due to
the explosive spread of AIDS in parts of the developing world
with high seroprevalence for KSHV, KS has reached epidemic
proportions (Dourmishev et al., 2003). AIDS-KS patients in
sub-Saharan countries often have high tumor burdens and
may have rapid and fatal disease progression. Similarly, even
with a dramatic decline in incidence with the introduction of
HAART, KS continues to be an important cause of morbidity in
patients with AIDS in the developed world (Cheung et al.,
2005). Despite ongoing efforts, an optimal treatment for this
neoplasm is at present unavailable (Pantanowitz and Dezube,
2004).
Of interest, compelling data obtained using transgenic mouse
models suggest that vGPCRmay be the KSHV gene responsible
for the development of KS (Guo et al., 2003; Montaner et al.,
2003; Sodhi et al., 2004a; Yang et al., 2000). The KSHV-encoded
vGPCR is a member of the family of CXC chemokine G protein-
linked receptors that exhibits ligand-independent, constitutive
activity (Arvanitakis et al., 1997; Cesarman et al., 1996). This viral
receptor has been shown to be a powerful oncogene and to act
as a potent angiogenic activator by inducing the secretion of an-
giogenic factors from expressing cells (Arvanitakis et al., 1997;
Bais et al., 1998; Cesarman et al., 1996; Couty et al., 2001; Mon-
taner et al., 2004; Pati et al., 2001; Polson et al., 2002; Schwarz
and Murphy, 2001; Sodhi et al., 2000), suggesting a role for
vGPCR in both direct and paracrine cell transformation. Work
in endothelial cells has demonstrated that vGPCR can promote
activation of Akt in vitro (Montaner et al., 2001) and in vivo (Sodhi
et al., 2004c). However, the Akt downstream effectors required
for vGPCR to promote Kaposi’s sarcomagenesis are still un-
known (Sodhi et al., 2004b).
Here we demonstrate that direct and indirect (paracrine)
dysregulation of the Akt/TSC2/mTOR signaling pathway by the
KSHV vGPCR is essential for vGPCR oncogenesis, suggesting
that specific inhibitors of the mTOR pathway may represent
valuable therapeutic alternatives for KS. These findings have134profound implications for the treatment of patients with this
disease and further expose an essential role for the mTOR sig-
naling route in the proliferation and survival of endothelial cells
in response to angiogenic factors.
Results
Constitutive signaling to Akt in vGPCR-expressing cells
leads to activation of the TSC2/mTOR signaling pathway
Emerging evidence implicates a single KSHV gene, vGPCR, in
Kaposi’s sarcomagenesis (Guo et al., 2003; Montaner et al.,
2003; Yang et al., 2000) through its direct (Montaner et al.,
2001) and indirect (paracrine) (Sodhi et al., 2004c) induction of
Akt. However, the relative contribution of direct and paracrine
Akt activation as well as the Akt effectors required for vGPCR to
trigger KS initiation remains unclear (Sodhi et al., 2004b). In an ef-
fort to determine the signaling pathways downstream of Akt that
may contribute to vGPCR oncogenesis, we examined the profile
of phosphorylated Akt downstream molecules upon expression
of vGPCR. Cells expressing this viral receptor exhibited elevated
levels of phosphorylated Akt substrates, which were reduced
when exposed to the PI3 kinase inhibitor LY294002 (Figure 1B).
Figure 1. PI3K-dependent phosphorylation of proteins of the Akt/TSC2/
mTOR pathway by the KSHV vGPCR
A–C: Immunodetection of the levels of P-Akt or Akt (A), phosphorylated Akt
substrates (B), and P-TSC2 or TSC2 (C) of COS-7 cells transfected with mam-
malian vectors encoding for GFP (control), vGPCR, or vGPCR R143A
(R143A). Cells were treated with 50 mM LY294002 for 45 min where indicated.
D: Immunodetection of the levels of P-Akt, Akt, P-mTOR, mTOR, P-p70 S6K,
p70 S6K, P-4EBP1, or 4EBP1 of COS-7 cells transfected with mammalian vec-
tors encoding for GFP (control), vGPCR, or vGPCR R143A (R143A). Cells were
treated with 50 mM LY294002 or 50 nM rapamycin (Rap) for 45 min where
indicated.CANCER CELL AUGUST 2006
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(R143A) (Ho et al., 2001)were unable to promote phosphorylation
of Akt (Figure 1A) or its substrates (Figure 1B). These results dem-
onstrate that vGPCR-expressing cells constitutively signal to Akt
and its downstream effectors in a PI3K-dependent manner.
Of note, phosphorylation of a protein with a molecular weight
of approximately 200 kDawas potently induced in cells express-
ing vGPCR but was completely reversed upon treatment with
LY294002.Thisbandcorresponded in size toa recently identified
Akt substrate, the tumor suppressor protein TSC2 (Dan et al.,
2002; Inoki et al., 2002; Manning et al., 2002; Potter et al.,
2002). Indeed, we observed elevated levels of phosphorylated
TSC2 in vGPCR-expressing cells (Figure 1C). Using inactive
and agonist-dependent mutants of vGPCR (R143A and R143Q,
respectively) (Ho et al., 2001), we further observed that the phos-
phorylation of this tumor suppressor protein was, in part, a direct
consequence of intracellular signaling pathways initiated in
vGPCR-expressing cells (Figure 1C and data not shown).
The recent observation that Akt phosphorylation of TSC2 is
a key step in the regulation of the mTOR pathway prompted us
to explore whether TSC2 phosphorylation triggered by vGPCR
affects the activation of that signaling route. mTOR is a serine/
threonine kinase that regulates translation in response to nutri-
ents/growth factors by phosphorylating components of the pro-
tein synthesis machinery, including p70 S6K 4EBP1 (Schmelzle
and Hall, 2000). We found that vGPCR-expressing cells have
elevated levels of phosphorylated mTOR (Figure 1D). Cells
expressing the viral receptor also showed elevated levels of
phosphorylated p70 S6K and 4EBP1 (Figure 1D). Similar to
mTOR, phosphorylation of both p70 S6K and 4EBP1 was abol-
ished in the presence of LY294002. Moreover, when we used
the macrolide rapamycin, a potent mTOR inhibitor that has
been shown to be remarkably specific for the inhibition of that
serine/threonine kinase (Davies et al., 2000; Sabers et al.,
1995), vGPCR induction of p70 S6K and 4EBP1 phosphorylation
wascompletely reversed.Collectively, these results suggest that
vGPCR induces the phosphorylation and inactivation of the tu-
mor suppressor protein TSC2, thereby promoting the induction
of mTOR activity through the activation of the PI3K/Akt signaling
pathway.
mTOR downstream effectors are phosphorylated
in vGPCR experimental and human KS lesions
We next set out to explore whether mTOR may play a role in
vGPCR oncogenesis in vivo. To this end, we took advantage
of a recently described KS animal model (TIE2-tva) in which vas-
cular endothelial cells of mice can be specifically targeted by
retroviral transduction (Figure 2A) (Montaner et al., 2003; Sodhi
et al., 2004c). TIE2-tva transgenic mice infected with retrovirus
(RCAS) carrying the gene vGPCR (RCAS-vGPCR) developed
vascular tumors that are remarkably similar to human KS
(Figures 2B and 2C). Immunohistochemical analysis of these
tumors revealed high levels of phosphorylated Akt as well as
phosphorylated S6 ribosomal protein, a substrate of the mTOR
effector p70 S6K (Figure 2B), suggesting that activation of
mTOR and its downstream effectors may play a role in vGPCR
sarcomagenesis in vivo.
Identification of a possible role of TSC2/mTOR in experimen-
tal (vGPCR) Kaposi’s sarcomagenesis prompted us to study the
activation of this pathway in human KS. To this end, we exam-
ined biopsies of cutaneous KS lesions from patients withCANCER CELL AUGUST 2006AIDS-associated KS. Immunohistochemical staining revealed
high levels of phospho-Akt in human KS tumor cells that corre-
lated with elevated levels of phospho-S6 ribosomal protein in all
samples tested (8/8) (Figure 2C). Collectively, these results sup-
port a role for the TSC2/mTOR pathway in human Kaposi’s sar-
comagenesis.
vGPCR activates mTOR through both direct
and paracrine mechanisms
Immunostaining of experimental (vGPCR) and humanKS lesions
revealed that S6 ribosomal protein is phosphorylated in a signif-
icant proportion of tumor cells (Figures 2B and 2C) despite evi-
dence that vGPCR expression is confined to a small percentage
of cells in those lesions (Chiou et al., 2002;Montaner et al., 2003;
Yang et al., 2000). In this regard, it has previously been shown
that vGPCR activates Akt through both direct and indirect (para-
crine) mechanisms (Sodhi et al., 2004c). Thus, we set out to de-
termine whether the paracrine secretions elaborated by
vGPCR-expressing cells could be involved in the activation of
the mTOR pathway in KS tumors. We treated immortalized
murine (SVECs) as well as primary human (HMVEC) endothelial
cells with conditioned media from cells expressing vGPCR or its
inactive mutant, R143A. Figure 3A shows that only secretions
from vGPCR-expressing cells induced phosphorylation of S6 ri-
bosomal protein in treated cells and that this event was inhibited
in the presence of rapamycin, suggesting that vGPCR paracrine
secretions may activate mTOR in bystander endothelial cells in
KS lesions. We then treated HMVEC with individual cytokines,
chemokines, or angiogenic growth factors previously shown to
be secreted in response to vGPCR expression at concentrations
similar to what are found in vGPCR-conditioned media (Jensen
et al., 2005; Montaner et al., 2004). Figure 3B shows that those
ligands induced the phosphorylation of S6 ribosomal protein in
endothelial cells. Collectively, these results demonstrate that
vGPCR can activate mTOR through both direct and indirect
(paracrine) mechanisms.
vGPCR activation of the PI3K/Akt pathway promotes
cell proliferation primarily through its upregulation
of the TSC2/mTOR signaling pathway
The observation that vGPCR expression leads to the direct and
paracrine activation of the mTOR signaling route in vitro and in
vivo suggests that this proliferative pathway may contribute to
the potent sarcomagenic potential of this enigmatic viral onco-
gene. However, vGPCR has also been shown to induce the
activity of a number of intracellular signaling molecules, includ-
ing ERK1/2, JNK, and p38 (Bais et al., 1998; Munshi et al., 1999;
Sodhi et al., 2000), which in turn may also promote the expres-
sion of growth-promoting genes. To explore the relative contri-
bution of these pathways to vGPCR-induced cell proliferation,
we cultured endothelial cells stably expressing vGPCR
(EC-vGPCR) in the presence of increasing concentrations of
pharmacologic inhibitors of each of those signaling routes.
Figure 4A shows that the activation of PI3K, mTOR, ERK1/2,
JNK, and p38 in vGPCR-expressing cells could be effectively
blocked by their corresponding inhibitors. However, only treat-
ment with LY294002 or rapamycin had an impact on the prolif-
eration of vGPCR-expressing cells (Figure 4B). In contrast, phar-
macological inhibition of the ERK1/2, JNK, or p38 signaling
pathways did not significantly affect the proliferation of
EC-vGPCR (Inukai et al., 2004; Sodhi et al., 2000) (Figure 4B).135
A R T I C L EFigure 2. Levels of P-Akt and P-S6 ribosomal pro-
tein in vGPCR experimental and human KS
A: Schematic illustrating the oncogenic poten-
tial of vGPCR when specifically expressed in the
vascular endothelium of mice using the TIE2-tva
transgenic mouse model.
B: Representative H&E staining and immunohis-
tochemical detection of the levels of phosphor-
ylated Akt (P-Akt) and phosphorylated S6 ribo-
somal protein (P-S6) of a Kaposi-like sarcoma
formed in the TIE2-tva transgenic mouse model
after injection with RCAS-vGPCR (105 IU). The
cells demonstrate high cytoplasmic immunore-
activity for both P-Akt and P-S6. Scale bar, 50 mm.
C: Representative H&E staining and immunohis-
tochemical detection of the levels of P-Akt and
P-S6 of a human AIDS-KS tissue. Most tumor (spin-
dle) cells react with P-Akt and P-S6. Scale bar,
50 mm.The sensitivity to rapamycin, as assessed by the IC50 (50% in-
hibitory concentration), was approximately 0.2 nM, achieving
IC80 values with approximately 1 nM of compound. These re-
sults mirrored the effects of the treatment of EC-vGPCR cells
with the PI3 kinase inhibitor LY294002 (Figure 4B), suggesting
that vGPCR activation of the PI3K/Akt signaling pathway may
promote endothelial cell proliferation in part through the upregu-
lation of mTOR activity.
To further explore the role of the TSC2/mTOR pathway in
vGPCR-mediated cell proliferation, we generated a vGPCR-ex-
pressing endothelial cell line stably overexpressing wild-type
Rheb (EC-vGPCR/Rheb). Rheb is unique among members of
the small GTPase family in that the regulation of its function oc-
curs predominately through its inactivation by Rheb GAPs (e.g.,
TSC2) rather than its activation by Rheb guanidine exchange
factors (GEFs) (Im et al., 2002). Thus, overexpression of Rheb
can bypass the need for Akt inactivation of TSC2 to induce
mTOR activity (Figure 4C). Indeed, EC-vGPCR/Rheb cells
were insensitive to inhibition of mTOR by LY294002 but136remained sensitive to rapamycin inhibition of mTOR
(Figure 4D), confirming that overexpression of Rheb bypasses
the requirement for PI3K activation of Akt to promote mTOR
activity.
We next exposed EC-vGPCR/Rheb cells to increasing con-
centrations of the PI3 kinase inhibitor LY294002. Rheb strongly
protected vGPCR-expressing cells from the ability of LY294002
to inhibit cell proliferation (Figure 4E), increasing the IC50 almost
20-fold. Conversely, overexpression of Rheb had no effect on
the ability of rapamycin to inhibit cell growth (Figure 4E). Collec-
tively, these results implicate mTOR as an essential Akt effector
involved in the promotion of cell proliferation by vGPCR.
Activation of the TSC2/mTOR signaling pathway
is required for vGPCR tumorigenesis
These observations, combined with the lack of effective treat-
ment strategies for KS, prompted us to examine pharmacolog-
ical agents that may target the mTOR pathway in vivo, with the
aim of assessing the potential clinical benefit of such drugs forCANCER CELL AUGUST 2006
A R T I C L Ethe treatment of KS patients. To address this question, we
established allografts with EC-vGPCR in athymic nu/nu mice
and then treated animals with either rapamycin or vehicle, intra-
peritoneally, after tumors had been established. Drug toxicity,
as assessed by weight loss, was minimal in the rapamycin-
treated group (reduction <5%) during the duration of the study
period (data not shown). Tumor regression in treated animals
was observed within 2 days after the beginning of the treatment,
and inhibition of tumor growth was sustained for the duration of
the experiment (Figure 5A). At the end of the study (day 53), we
observed that, while the average weight of vehicle-treated
tumors was 1180 mg, an almost 6-fold increase in 14 days,
the rapamycin-treated group demonstrated minimal growth
over the same period, with an average tumor weight of 280
mg on day 53 (Figure 5A), representing only a 1.2-fold increase
in tumor mass 2 weeks after the initiation of the treatment with
the drug. Tumors from rapamycin-treated animals showed
decreased cellularity, and immunohistochemical analysis of
these tumors demonstrated a dramatic reduction in the levels
of phospho-S6 ribosomal protein compared to control animals
(Figure 5B). Tumor cell proliferation, as assessed by the incorpo-
ration of 5-bromo-2-deoxyuridine (BrdU), from treated animals
was also diminished compared to control animals (Figure 5B).
Of note, treatment of animals with rapamycin prior to establish-
ment of tumors completely prevented tumor formation (data not
shown). Collectively, these results suggest that activation of the
TSC2/mTOR pathway is necessary for vGPCR sarcomagenesis.
Activation of the mTOR signaling pathway is sufficient
to render expressing endothelial cells sarcomagenic
To further examine the contribution of vGPCR activation of
Rheb/mTOR to endothelial cell transformation in vivo, we next
generated an immortalized endothelial cell line stably
Figure 3. Paracrine activation of mTOR by vGPCR
A: Phosphorylation of S6 ribosomal protein in murine (SVEC) or human
(HMVEC) endothelial cells after 30 min treatment with conditioned media
(supernatant) from NIH3T3 stably expressing GFP (control), vGPCR, or the in-
active vGPCR mutant (R143A), or conditioned media from 293T cells trans-
fected with mammalian vectors encoding these proteins. Cells were pre-
treated with 50 nM rapamycin (Rap) for 45 min where indicated.
B: Immunodetection of the levels of phospho-S6 ribosomal protein of HMVEC
treated for 15 min with IL8 (50 ng/ml), GROa (50 ng/ml), VEGF (5 ng/ml), PDGF
(2.5 ng/ml), IL1b (0.0025 ng/ml), IL10 (2.5 ng/ml), IL6 (0.25 ng/ml), TNFa
(0.05 ng/ml), IP10 (50 ng/ml), SDF1a (50 ng/ml), or MIG (50 ng/ml). Untreated
cells served as a control (control).CANCER CELL AUGUST 2006overexpressing wild-type Rheb (EC-Rheb) and measured its tu-
morigenic potential in athymic nu/numice. Surprisingly, expres-
sion of Rheb alone was sufficient to render overexpressing en-
dothelial cells oncogenic (Figure 6A). The tumors were
composed primarily of sheets of atypical spindle-shaped cells
interrupted by narrow vascular slits (Figure 6B). Immunohisto-
chemical analysis of these lesions revealed high cytoplasmic
immunoreactivity for phosphorylated S6 ribosomal protein in
most of the malignant tumor cells (Figure 6B). These results
suggested that vGPCR activation of mTOR may be sufficient
to render expressing endothelial cells sarcomagenic.
Direct activation of mTOR in vGPCR-expressing cells
is not sufficient for vGPCR sarcomagenesis in vivo
As vGPCR activates mTOR through both direct and paracrine
mechanisms,wenext set out to examine the relative contribution
of each to vGPCR sarcomagenesis. To this end, we generated
a cell line coexpressing vGPCRalongwith a rapamycin-resistant
mTORmutant that bears an SI substitution in the FKBP12-rapa-
mycin binding domain (EC-vGPCR/RR-mTOR) (Edinger et al.,
2003). Figure 7A shows that the rapamycin-resistant mTOR
mutant strongly protected vGPCR-expressing cells from the
ability of rapamycin to inhibit cell proliferation in vitro, increasing
the IC50 almost 280-fold, confirming that coexpression of
RR-mTOR renders endothelial cells expressing vGPCR less
sensitive to the antiproliferative effects of rapamycin.
We next set out to establish the sensitivity of tumors formed
by EC-vGPCR/RR-mTOR to rapamycin in vivo. To this end,
we established allografts with EC-vGPCR/RR-mTOR cells in
athymic nu/nu mice. Similar to EC-vGPCR tumors, allografts
formed from EC-vGPCR/RR-mTOR were composed of rare (ra-
pamycin-insensitive) cells coexpressing vGPCR and RR-mTOR
(Figure 7B), with themajority of the tumor composed of recruited
(rapamycin-sensitive) host cells. We then treated animals with
either rapamycin or vehicle after tumors had been established.
Surprisingly, despite their resistance to the inhibitory effects of
rapamycin in vitro, growth of tumors formed from EC-vGPCR/
RR-mTOR was strongly inhibited by rapamycin in vivo (Fig-
ure 7C). This suggests that the effect of rapamycin on vGPCR
sarcomagenesis is not dependent on the direct activation of
mTOR in vGPCR-expressing cells. Rather, the profound sensi-
tivity of these tumors to treatment with rapamycin may be due
in part to the inhibition of the paracrine activation of mTOR in
neighboring (bystander) cells by the angiogenic factors elabo-
rated by vGPCR-expressing cells.
Endothelial cells are remarkably susceptible
to transformation through activation
of the mTOR signaling pathway
The observation that paracrine activation of the TSC2/mTOR
pathway by angiogenic factors in experimental KS tumors plays
a key role in vGPCR sarcomagenesis suggests that this pathway
may provide significant insight into Kaposi’s sarcomagenesis.
Indeed, a transgenic mouse model expressing vGPCR under
the ubiquitous SV40 promoter manifests only vascular tumors
(Guo et al., 2003), suggesting that endothelial cells may be
uniquely sensitive to activation of mTOR by vGPCR. Of note,
the phenotypes of two recent animal models in which a single
allele of either TSC1 or TSC2 was genetically interrupted have
a similar poorly understood predisposition for vascular tumors
(Kwiatkowski et al., 2002; Onda et al., 1999). The major tumors137
A R T I C L EFigure 4. Activation of the PI3K/Akt pathway by vGPCR induces cell proliferation through the TSC2/mTOR signaling pathway
A: Pharmacological inhibition of vGPCR signaling pathways in expressing endothelial cells (EC-vGPCR). Cells were treated with a PI3K inhibitor (LY294002; 1
mM), an mTOR inhibitor (rapamycin [Rap]; 1 nM), an ERK1/2 inhibitor (U0126; 10 mM), a JNK inhibitor (SP600125; 5 mM), or a p38 inhibitor (SB203580; 10 mM). Lysates
were analyzed by Western blot using a phospho-antibody for the corresponding kinase substrate.
B: Effect of the treatment with increasing doses of LY294002, rapamycin (Rap), U0126, SP600125, or SB203580 on the proliferation of EC-vGPCR. Results are
illustrated as percentage of cell proliferation relative to untreated parental (SVEC) control cells. The results are the mean 6 SEM of triplicate samples from
a single representative experiment that was repeated three times with similar results.
C: Schematic demonstrating the regulation of mTOR activity through Akt phosphorylation (and inhibition) of the Rheb GAP, TSC2. Akt-dependent inactivation
of TSC2 can be bypassed by overexpressing wild-type Rheb, thereby promoting mTOR activity in the presence of inhibitors of PI3K (e.g., LY294002), but not
inhibitors of mTOR (e.g., rapamycin).
D: Immunodetection of the levels of AU5-tagged Rheb wild-type, P-mTOR, mTOR, P-p70 S6K, p70 S6K, P-4EBP1, or 4EBP1 in SVECs stably transfected with mam-
malian vectors encoding for GFP (control) or wild-type Rheb (Rheb). Cells were treated with 50 mM LY294002 or 50 nM rapamycin (Rap) for 45 min where
indicated.
E: Effects of treatment with increasing doses of LY294002 or rapamycin (Rap) on the proliferation of EC-vGPCR cells or EC-vGPCR cells overexpressing Rheb
(EC-vGPCR/Rheb). Results are illustrated as percentage of cell proliferation relative to untreated parental (SVEC) control cells. The results are the mean6 SEM
of triplicate samples from a single representative experiment that was repeated three times with similar results. IC50s for each line are shown.involving vascular endothelial cells in these animals are liver
hemangiomas (Figure 8A), occurring in more than half of
TSC2+/2 mice. Approximately 12% of TSC2+/2 mice develop
vascular endothelial sarcomas (angiosarcomas), of which
100%manifest as dermal vascular sarcomas in the tail (approx-
imately 1/4) or paws (approximately 3/4) (Figure 8B). Similar to
TSC2+/2 mice, almost all RCAS-vGPCR-infected TIE2-tva
mice developed benign liver hemangiomas (Figure 8A), while
dermal vascular sarcomas in the tail and paw were also ob-
served in 100% of RCAS-vGPCR-infected TIE2-tva mice that
developed solid tumors (Figure 8B). The latter is in striking con-
trast to the lack of dermal tumors seen in TIE2-tvamice when in-
fected with other potent oncogenes, including the polyomamid-
dle T antigen, H-ras V12, or neu (data not shown). Moreover,
when infected with other oncogenes, TIE2-tva mice manifested
only benign hemangiomas that were unable to progress to the
solid sarcomas observed in RCAS-vGPCR-infected TIE2-tva138mice and also in TSC2+/2mice (data not shown). The predispo-
sition for hemangiomas and vascular sarcomas in both TSC2+/2
mice and vGPCR transgenic animals suggests that endothelial
cells may be uniquely sensitive to transformation through the
TSC2/mTOR signaling pathway. Moreover, the unique predilec-
tion of both TSC2+/2 mice and vGPCR transgenic animals to
dermal vascular sarcomas—similar to human KS—further impli-
cates mTOR as a key player in Kaposi’s sarcomagenesis.
Discussion
The recent identification of KSHV as the viral etiologic agent for
KS has provided a unique opportunity to uncover the molecular
pathogenesis of this enigmatic neoplasm (Chang et al., 1994). In
this regard, emerging evidence suggests that dysregulated ex-
pression of a KSHV-encoded gene, vGPCR, may trigger the ini-
tiation of KS (Sodhi et al., 2004a). Indeed, endothelial-specificCANCER CELL AUGUST 2006
A R T I C L Eretroviral transduction of vGPCR is sufficient to promote the for-
mation of vascular sarcomas in mice that are strikingly similar to
human KS lesions and share a unique predilection for the skin
(Montaner et al., 2003). Similar results have been obtained using
twoother transgenic animalmodels (Guo et al., 2003; Yang et al.,
2000). Collectively, these results suggest that this oncogenemay
hold the key to understanding—and therefore treating—this un-
usual cancer. Current work has focused on unraveling the com-
plex signaling networks regulated by this unique viral oncogene,
and how they may contribute to Kaposi’s sarcomagenesis.
Here we show that vGPCR stimulates the phosphorylation
and inactivation of TSC2 through both direct and indirect
Figure 5. Activation of the TSC2/mTOR signaling pathway is required for
vGPCR oncogenesis
A: Effect of the treatment with an mTOR inhibitor of EC-vGPCR allografts es-
tablished in athymic nu/nu females. Mice were treated with one cycle (ar-
rows) of either rapamycin (Rap) (10 mg/kg/day) or equivalent volume of ve-
hicle intraperitoneally for 5 consecutive days as described in the
Experimental Procedures. The results are expressed as mean tumor weight
(mg) 6 SEM. Data are from a representative independent experiment
that was repeated two times with similar results.
B: H&E staining, relative levels of P-S6 ribosomal protein, and BrdU incorpora-
tion in representative sections of vehicle- and rapamycin-treated EC-
vGPCR tumor tissue. Rapamycin-treated tumors show decreased cellularity,
fewer mitotic figures, and decreased BrdU staining, correlating with
a marked reduction in P-S6 immunoreactivity. Scale bar, 50 mm.CANCER CELL AUGUST 2006(paracrine) mechanisms, thereby promoting the activation of
the mTOR signaling pathway. Our current work predicts that
this pathway may play an essential role in the promotion of
KSHV pathogenesis. During the normal KSHV life cycle, we pro-
pose that direct activation of this pathway in lytic vGPCR-ex-
pressing cells may serve to facilitate efficient viral replication,
while indirect (paracrine) activation of mTOR by the proangio-
genic factors secreted by cells expressing vGPCRmay promote
the proliferation of recruited neighboring endothelial cells, which
can then be infected by the newly formed progeny virion (Sodhi
et al., 2004a). Conversely, it can be speculated that nonlytic ex-
pression of vGPCR may promote dysregulation of the mTOR
pathway, leading to both direct and paracrine endothelial cell
transformation. Indeed, we observe here that vGPCR activation
of mTOR is necessary and sufficient for the ability of this vGPCR
to render expressing endothelial cells oncogenic. Moreover,
mice haploinsufficient for TSC2—which genetically mimic
vGPCR inhibition of this protein—are predisposed to vascular
sarcomas remarkably similar to KS, providing genetic evidence
demonstrating that the profound sensitivity of endothelial cells
to KSHV sarcomagenesis may be a consequence of the dysre-
gulation of the mTOR pathway by vGPCR.
We further observe that paracrine activation of mTOR by an-
giogenic factors elaborated by vGPCR-expressing cells plays
an essential role in vGPCR sarcomagenesis. Although it is pos-
sible that the resistance of the mTOR Ser2035/Ile (RR-mTOR)
mutant to rapamycin in vitro may not be reflective of its sensitiv-
ity to this molecule in vivo, we observed no statistically signifi-
cant difference in tumor growth after treatment with rapamycin
in tumors formed from vGPCR-expressing endothelial cells in
the presence or absence of the RR-mTORmutant. These results
suggest that that direct activation of mTOR in vGPCR-express-
ing cells is not sufficient to explain the potent oncogenic poten-
tial of vGPCR and implicate vGPCR paracrine activation of
mTOR in vGPCR sarcomagenesis. Alternatively, it is reasonable
Figure 6. Activation of the TSC2/mTOR signaling pathway is sufficient to
transform expressing endothelial cells
A: Tumor allografts were established in athymic nu/nu mice by injecting im-
mortalized murine endothelial cells (SVEC) or SVECs expressing vGPCR (EC-
vGPCR) or Rheb (EC-Rheb). The results are expressed as mean tumor weight
(mg) 6 SEM. Data are from a representative independent experiment that
was repeated two times with similar results.
B: H&E staining and relative levels of P-S6 ribosomal protein in a representa-
tive section of EC-Rheb tumor tissue. The tumor is composed of atypical spin-
dle-shaped tumor cells with narrow vascular structures, similar to tumors
formed from endothelial cells expressing vGPCR. P-S6 shows cytoplasmic im-
munoreactivity in most of the tumor cells. Scale bar, 50 mm.139
A R T I C L EFigure 7. Direct activation of mTOR is not suffi-
cient for vGPCR sarcomagenesis in vivo
A: Inhibition of proliferation of endothelial cells
expressing vGPCR (EC-vGPCR) or coexpressing
vGPCR and the rapamycin-resistant mTOR mu-
tant (EC-vGPCR/RR-mTOR) by increasing doses
of rapamycin (Rap). Results are illustrated as per-
centage of cell proliferation relative to un-
treated parental (SVEC) control cells. The results
are the mean 6 SEM of triplicate samples from
a single representative experiment that was re-
peated two times with similar results.
B: Immunohistochemical staining showing ex-
pression of AU1-tagged RR-mTOR in a small num-
ber of tumor cells within allografts established in
athymic nu/nu females upon injection of EC-
vGPCR/RR-mTOR. Scale bar, 50 mm.
C: Effect of the treatment with the mTOR inhibitor
rapamycin on tumors formed from EC-vGPCR or
EC-vGPCR/RR-mTOR. Mice were treated with
one cycle (arrows) of either rapamycin (Rap)
(10 mg/kg/day) or equivalent volume of vehicle
intraperitoneally for 5 consecutive days, as
described in the Experimental Procedures. The
results are expressed as mean tumor weight
(mg) 6 SEM. Data are from a representative
independent experiment that was repeated
once with similar results.to argue that the impact of the rare vGPCR-expressing cells is
significantly diminished once tumors have formed; conse-
quently, expression of the RR-mTOR mutant would have no im-
pact on tumor growth if only expressed in these rare tumor cells.
However, we have recently observed that specifically targeting
only the rare vGPCR-expressing cells in established tumors is
sufficient to induce apoptosis in adjacent (bystander) KSHV la-
tent gene-expressing tumor cells (Montaner et al., 2006), further
supporting an essential role for the paracrine secretions elabo-
rated by vGPCR-expressing cells in Kaposi’s sarcomagenesis.
Taken together, these results implicate the vGPCR direct and
paracrine activation of the TSC2/mTOR pathway as a critical
event in KSHV pathogenesis and suggest that targeting this
pathway may prove to be an effective therapeutic intervention
for the treatment of patients with KS.
Of note, in two recent small nonrandomized prospective stud-
ies, the immunosuppressive drug in HIV-negative, renal trans-
plant recipients who had biopsy-proven iatrogenic KS was
switched from cyclosporine to the mTOR inhibitor rapamycin
(Campistol et al., 2004; Stallone et al., 2005). Remarkably, 3
months after rapamycin therapy was initiated (and cyclosporine
therapy was stopped), all cutaneous KS lesions had disap-
peared in all patients. As controls (e.g., untreated patients)
were not feasible in these studies, it is reasonable to argue
that the previously reported ‘‘protumorigenic’’ effects of cyclo-
sporine, combined with the more profound immunosuppressive
effects of this agent compared to rapamycin, may have contrib-
uted to the regression of KS tumors once treatment with cyclo-
sporine was stopped. However, in light of our current observa-
tions, we propose that the dramatic regression of KS tumors
in renal transplant patients treated with rapamycin is likely to
be a consequence of the inhibition of vGPCR dysregulation of
the TSC2/mTOR pathway in KS tumors. This suggests that, in
addition to patients with iatrogenic KS, rapamycin may be an ef-
fective treatment for patients with other forms of KS (AIDS-re-
lated, endemic, and classic), providing the basis for the early140assessment of molecules inhibiting mTOR (e.g., rapamycin [si-
rolimus; Wyeth] and its derivatives: temsirolimus [CCI-779;
Wyeth], everolimus [RAD-001; Novartis Pharma AG], and
AP-23573 [Ariad Pharmaceuticals]) in patients with cutaneous
and/or systemic KS. As AIDS-KS is the most frequent cancer
among HIV-infected individuals and endemic KS is the most
common neoplasm in children and adult men in parts of the de-
veloping world, our results have important implications for the
treatment of a significant population of patients who currently
have a paucity of therapeutic options (Mitsuyasu, 2000; Panta-
nowitz and Dezube, 2004).
Our results may also have broader implications. It has previ-
ously been reported that the antitumor effects of rapamycin
may, in part, be a consequence of its antiangiogenic effects
(Brugarolas et al., 2003; Humar et al., 2002; Mayerhofer et al.,
2002). Rapamycin has been shown to inhibit the secretion of
vascular endothelial growth factor (VEGF) by preventing
mTOR activation of the transcription factor hypoxia inducible
factor-1a (HIF-1a) (Hudson et al., 2002). As vGPCR has also
been shown to upregulate VEGF secretion by acting on HIF-
1a (Sodhi et al., 2000), it could be postulated that the effect of
rapamycin on vGPCR oncogenesis is a consequence of its inhi-
bition of vGPCR promotion of VEGF secretion. However, the ad-
dition of exogenous VEGF failed to rescue rapamycin-treated (or
LY294002-treated), vGPCR-expressing endothelial cells from
pharmacologic inhibition of cell proliferation (data not shown;
also Montaner et al., 2001), suggesting that the effects of rapa-
mycin on vGPCR-expressing endothelial cells are not depen-
dent on its previously reported inhibitory effects on VEGF secre-
tion. Moreover, we provide evidence here that demonstrates
that activation of the mTOR pathway may, in fact, play a more
central role in the angiogenic response to growth factors and in-
flammatory mediators.
Indeed, all angiogenic growth factors tested potently acti-
vated the TSC2/mTOR pathway in treated endothelial cells.
Moreover, while prior reports have demonstrated a significantCANCER CELL AUGUST 2006
A R T I C L Evariability in the sensitivity of cell lines to treatment with rapamy-
cin in vitro (IC50s ranging from 1 nM for rhabdomyosarcoma cell
lines to >5000 nM for colon cancer cell lines; see Huang et al.,
2003 for review), vGPCR-expressing endothelial cells appeared
to be remarkably sensitive to treatment with rapamycin. As KS
has historically served as a powerful model of the complex rela-
tionship between tumorigenesis and angiogenesis, it is tempting
to speculate that rapamycin’s antitumor and antiangiogenic ef-
fects may be a consequence of the essential role for the mTOR
pathway in endothelial cell proliferation and survival in response
to secreted angiogenic factors. Indeed, the vascular specificity
of the prosarcomagenic effects of overactivation of the mTOR
pathway, combined with recent evidence for the potent antian-
giogenic effects of inhibiting this pathway, point to the necessity
for precise regulation of mTOR activity for normal endothelial
cell growth and survival and further expose this pathway as an
essential target for the development of novel mechanism-based
antiangiogenic therapies for other human cancers.
Experimental procedures
Expression plasmids and reagents
The expression plasmids for vGPCR, R143A, R143Q, and EGFP have been
previously described (Sodhi et al., 2004c). The human Rheb sequence was
Figure 8. vGPCR-expressing mice and TSC2+/2 animals develop similar vas-
cular tumors
A: Representative H&E staining of a liver hemangioma formed in the TIE2-tva
transgenic mouse model after injection with RCAS-vGPCR (105 IU) (vGPCR)
or in TSC2-deficient animals (TSC2+/2). Scale bar, 50 mm.
B: Gross pathology and representative H&E staining of a Kaposi-like sar-
coma formed in the TIE2-tva transgenic mouse model after injection with
RCAS-vGPCR (105 IU) (vGPCR) or an angiosarcoma formed in TSC2-defi-
cient animals (TSC2+/2). Scale bar, 50 mm.CANCER CELL AUGUST 2006amplified from human keratinocyte cDNA and subcloned into the pCEFL-
AU5 expression vector. The rapamycin-resistant mTOR mutant (RR-
mTOR), containing an SI substitution in the FKBP12-rapamycin binding do-
main, was kindly provided by Robert T. Abraham. Cytokines, chemokines,
and growth factors were obtained from Pepro Tech. The inhibitors
LY294002, rapamycin, U0126, SP600125, and SB203580 were purchased
from Calbiochem. For in vivo studies, rapamycin was provided by the Devel-
opment Therapeutics Program, National Cancer Institute (NCI), dissolved in
100% ethanol, and further diluted in an aqueous solution of 5.2% Tween-80
and 5.2% PEG immediately before use (Wendel et al., 2004).
Cell lines, transfections, and cell proliferation assays
Immortalized murine endothelial cells (SVEC), 293T cells, and COS-7 cells
were cultured as previously described (Montaner et al., 2003). Primary hu-
man dermal microvascular endothelial cells (HMVEC) were obtained from
Cambrex and cultured in EGM-2 MV. Transfections were performed as pre-
viously described (Sodhi et al., 2004c). SVEC stable cell lines (EC cell lines)
were obtained as has previously been described (Sodhi et al., 2004c). Cell
lines coexpressing vGPCR along with Rheb or RR-mTOR were selected
with blasticidin after transfection of EC-vGPCR with the pTracer-EF/Bsd
plasmid (Invitrogen) encoding for the corresponding gene. All stable cell lines
were pooled cultures. Cell proliferation was determined using the crystal vi-
olet staining assay (Montaner et al., 1995).
Mouse strains and tumorigenesis assays
Generation and characterization of the TIE2-tva transgenic mouse line has
been described elsewhere (Montaner et al., 2003). The athymic nu/nu nude
females were purchased from Harlan Sprague Dawley. The animals received
food and water ad libitum and were housed in the Association for Assess-
ment and Accreditation for Animal Care-approved animal facility of the Uni-
versity of Maryland at Baltimore under the care and management of full-time
veterinarians and veterinary staff. All procedures involving animals were ap-
proved by the Institutional Animal Care and Use Committee. Tumorigenesis
assays were performed as previously described (Montaner et al., 2003). For
drug treatment, tumor-bearing animals were randomly grouped (control, n =
10; test, n = 10) and treated with rapamycin (10 mg/kg/day) or an equal vol-
ume of diluent. Treatment schedule was a single injection per animal per day,
given intraperitoneally for 5 consecutive days. For analysis, tumorweight was
determined as previously described (Sodhi et al., 2004c). At the end of the
study period, animals were euthanized for tissue retrieval. TSC2+/2 mice
used in this study were characterized previously (Onda et al. 1999).
Western blots and immunohistochemistry
Western blots and immunohistochemistry were performed as previously de-
scribed (Sodhi et al., 2004c). Antibodies recognizing Akt, P-Akt, TSC2, P-
TSC2, P-(Ser/Thr) Akt substrate, mTOR, P-mTOR, p70 S6K, P-p70 S6K,
4EBP1, P-4EBP1, P-S6 ribosomal protein, P-Elk1, P-cJun, and P-ATF2
were obtained from Cell Signaling. The antibody against the AU5 epitope
was purchased from Covance. For BrdU studies, mice were first given an in-
traperitoneal injection of BrdU (100 mg/kg) 2 hr prior to sacrifice.
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